SCHEMBL9607110

SCHEMBL9607110

CCC(CC)Oc1ccc(/C=C/C(=O)Nc2ccccc2C=O)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
RAB9A P51151 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
NPC1 O15118 3/20 0.57
TP53 P04637 2/20 0.57
CYP3A4 P08684 2/20 0.57
HPGD P15428 2/20 0.57
HIF1A Q16665 2/20 0.57
PKM P14618 2/20 0.57
KDM4E B2RXH2 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
HSD17B10 Q99714 1/20 0.57
ABCC4 O15439 1/20 0.57
HPGDS O60760 1/20 0.57
ABCB11 O95342 1/20 0.57
ALOX12 P18054 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13352112 0.89 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL13352244 0.88 MEN1 (0.71) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL17565741 0.88 PKM (0.60) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL13352093 0.87 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL2849459 0.86 MEN1 (0.78) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL2849455 0.86 MEN1 (0.78) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL13352146 0.85 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL14021155 0.84 BCHE (0.59) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL16215192 0.83 ALDH1A1 (0.62) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL14319164 0.83 MEN1 (0.58) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012068612-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION FIBROTECH THERAPEUTICS PTY LTD (AU) 2012-05-31 WO disclosed
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 US disclosed
WO-2008131481-A1 TREATMENT OF MESANGIOPROLIFERATIVE DISEASES FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-11-06 WO disclosed
WO-2008003141-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130497-A1 Therapeutic Compounds NFATC1, NAT1, AADAC ALDH1A1 199/4885MEN1 2640/4885KMT2A 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.